Literature DB >> 8109570

Risk of other cancers following Kaposi's sarcoma: relation to acquired immunodeficiency syndrome.

R J Biggar1, R E Curtis, T R Cote, C S Rabkin, M Melbye.   

Abstract

To evaluate the risk of another cancer among persons who initially developed Kaposi's sarcoma, the authors used data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute for the years 1973-1990. In persons under 70 years of age, 4,946 cases of Kaposi's sarcoma were observed during the period 1980-1990 (6,217 person-years of follow-up). On the basis of rates seen during the period prior to the epidemic of acquired immunodeficiency syndrome (AIDS), 169 cases were expected. Therefore, cases of Kaposi's sarcoma in this group were assumed to be AIDS-related, while cases occurring in older persons or during the 1970s were assumed to be non-AIDS-related. Rates were compared with the numbers of cases expected overall and by site on the basis of age-, sex-, and calendar year-specific rates from the SEER data. Among the 4,946 persons with AIDS-related Kaposi's sarcoma, the risk of developing non-Hodgkin's lymphoma through 1990 was increased 198-fold (95% confidence interval 169-232). However, the risk of all other cancers was only marginally increased (1.5-fold; 95% confidence interval 0.95-2.3), a risk that was probably biased upward because of ascertainment and misclassification. Among 491 persons with non-AIDS-related Kaposi's sarcoma, the relative risk of all cancers, including non-Hodgkin's lymphoma, was 0.9 (upper 95% confidence limit 1.2), and the risk of non-Hodgkin's lymphoma alone was 0.6 (upper 95% confidence limit 3.3). As of 1990, the risk of having another cancer following Kaposi's sarcoma was increased only in persons infected with human immunodeficiency virus, who were at high risk of non-Hodgkin's lymphoma but probably not of other cancers as a whole.

Entities:  

Mesh:

Year:  1994        PMID: 8109570     DOI: 10.1093/oxfordjournals.aje.a117008

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  17 in total

1.  Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation.

Authors:  Chen S Tan; Bruce J Dezube; Parul Bhargava; Patrick Autissier; Christian Wüthrich; Janice Miller; Igor J Koralnik
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

Review 2.  HIV infection and lymphoma.

Authors:  K L Grogg; R F Miller; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

3.  Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

Authors:  Athe M N Tsibris; Roger Paredes; Amy Chadburn; Zhaohui Su; Timothy J Henrich; Amy Krambrink; Michael D Hughes; Judith A Aberg; Judith S Currier; Karen Tashima; Catherine Godfrey; Wayne Greaves; Charles Flexner; Paul R Skolnik; Timothy J Wilkin; Roy M Gulick; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

4.  Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Authors:  Julia Bohlius; Kurt Schmidlin; Dominique Costagliola; Gerd Fätkenheuer; Margaret May; Anna Maria Caro-Murillo; Amanda Mocroft; Fabrice Bonnet; Gary Clifford; Anastasia Karafoulidou; Jose M Miro; Jens Lundgren; Genevieve Chene; Matthias Egger
Journal:  Antivir Ther       Date:  2009

5.  Successful unrelated bone marrow transplantation for a human immunodeficiency virus type-1-seropositive acute myelogenous leukemia patient following HAART.

Authors:  Yoko Oka; Haruko Tashiro; Mitsuho Mizutani-Noguchi; Ichiro Koga; Toshihiko Sugao; Ryosuke Shirasaki; Toshiyuki Miura; Nobu Akiyama; Kazuo Kawasugi; Shin Fujimori; Naoki Shirafuji
Journal:  Int J Hematol       Date:  2009-12-25       Impact factor: 2.490

6.  Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy.

Authors:  Fahad Mukhtar; Mmadili Ilozumba; Ovie Utuama; Oguz Cimenler
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

7.  Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005.

Authors:  A W Armstrong; K H Lam; E P Chase
Journal:  Epidemiol Infect       Date:  2012-03-12       Impact factor: 4.434

8.  Serological Assessment of 18 Pathogens and Risk of AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Gordana Halec; Tim Waterboer; Nicole Brenner; Julia Butt; W David Hardy; Gypsyamber DʼSouza; Steven Wolinsky; Bernard J Macatangay; Michael Pawlita; Roger Detels; Otoniel Martínez-Maza; Shehnaz K Hussain
Journal:  J Acquir Immune Defic Syndr       Date:  2019-03-01       Impact factor: 3.771

9.  Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002).

Authors:  V Ascoli; G Minelli; M Kanieff; R Crialesi; L Frova; S Conti
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

10.  Kaposi Sarcoma Incidence, Burden, and Prevalence in United States People with HIV, 2000-2015.

Authors:  Sally Peprah; Eric A Engels; Marie-Josèphe Horner; Analise Monterosso; H Irene Hall; Anna Satcher Johnson; Ruth M Pfeiffer; Meredith S Shiels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-06-23       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.